0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > CD79B

CD79B

Brief Information

Name:B-cell antigen receptor complex-associated protein beta chain
Target Synonym:B-Cell Antigen Receptor Complex-Associated Protein Beta Chain,B29,Immunoglobulin-associated B29 protein,Ig-beta,B-cell-specific glycoprotein B29,CD79B,CD79b Molecule,CD79b Molecule, Immunoglobulin-Associated Beta,IGB,CD79B Antigen (Immunoglobulin-Associated Beta),CD79b Antigen,AGM6
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:9
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

SCCHO-ATP171-Cell-based assay
 CD79B FACS

Expression analysis of human CD79B on CHO/Human CD79B Stable Cell Line by FACS.
Cell surface staining was performed on CHO/Human CD79B Stable Cell Line or negative control cell using APC-labeled anti-human CD79B antibody.

CDB-H52H3-SPR
 CD79B SPR

Polatuzumab captured on Protein G Chip can bind Human CD79B, His Tag (Cat. No. CDB-H52H3) with an affinity constant of 1.97 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

CDB-H82E3-ELISA
 CD79B ELISA

Immobilized Biotinylated Human CD79B, His,Avitag (Cat. No. CDB-H82E3) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-CD79B (Polatuzumab) Humanized Antibody with a linear range of 0.1-2 ng/mL (Routinely tested).

Synonym Name

CD79b,B29,IGB,Ig-beta

Background

B-cell antigen receptor complex-associated protein beta chain (CD79b) is also known as B-cell-specific glycoprotein B29, Ig-beta,Immunoglobulin-associated B29 protein, B29 and IGB, which is a single-pass type I membrane protein containing one Ig-like V-type ( immunoglobulin-like ) domain and one ITAM domain.CD79b is required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR).CD79b can enhance phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation. Defects in CD79b are the cause of agammaglobulinemia type 6 (AGM6) that is a primary immunodeficiency characterized by profoundly low or absent serum antibodies and low or absent circulating B cells due to an early block of B-cell development.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Polatuzumab vedotin RO-5541077-000; FCU-2711; DCDS-4501A; RG-7596; RO-5541077 Approved Genentech Inc Polivy United States Lymphoma, Large B-Cell, Diffuse Genentech Inc 2019-06-10 Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
Polatuzumab vedotin RO-5541077-000; FCU-2711; DCDS-4501A; RG-7596; RO-5541077 Approved Genentech Inc Polivy United States Lymphoma, Large B-Cell, Diffuse Genentech Inc 2019-06-10 Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
PRV-3279 HDM-3002; MGD-010; PRV-3279; CD32BxCD79B Phase 2 Clinical Macrogenics Inc Lupus Erythematosus, Systemic Details
CD19/79b Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) bi-4SCAR CD19/79b Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Lymphoma, B-Cell; Leukemia, B-Cell Details
TolDCB29 Phase 2 Clinical Umc Utrecht Arthritis, Rheumatoid Details
SHR-A1912 SHR-A1912 Phase 2 Clinical Shanghai Hengrui Pharmaceutical Co Ltd Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma Details
CD79b-19 CAR T Cells Therapy (Massachusetts General Hospital) Phase 1 Clinical Massachusetts General Hospital Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin Details
Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy(MD Anderson Cancer Center) JV-213 Phase 1 Clinical The University Of Texas MD Anderson Cancer Center Lymphoma, B-Cell; Lymphoma Details
NBT-508 Phase 1 Clinical Newbio Therapeutics Inc Lymphoma, B-Cell; Lymphoma, Non-Hodgkin Details
CD79b CAR-T cell therapy (Yake Biotechnology) Phase 1 Clinical Zhejiang University Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Biphenotypic, Acute Details
Iladatuzumab vedotin DCDS-0780A; RO-7032005 Phase 1 Clinical F. Hoffmann-La Roche Ltd Lymphoma, Non-Hodgkin Details
PRV-3279 HDM-3002; MGD-010; PRV-3279; CD32BxCD79B Phase 2 Clinical Macrogenics Inc Lupus Erythematosus, Systemic Details
CD19/79b Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) bi-4SCAR CD19/79b Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Lymphoma, B-Cell; Leukemia, B-Cell Details
TolDCB29 Phase 2 Clinical Umc Utrecht Arthritis, Rheumatoid Details
SHR-A1912 SHR-A1912 Phase 2 Clinical Shanghai Hengrui Pharmaceutical Co Ltd Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma Details
CD79b-19 CAR T Cells Therapy (Massachusetts General Hospital) Phase 1 Clinical Massachusetts General Hospital Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin Details
Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy(MD Anderson Cancer Center) JV-213 Phase 1 Clinical The University Of Texas MD Anderson Cancer Center Lymphoma, B-Cell; Lymphoma Details
NBT-508 Phase 1 Clinical Newbio Therapeutics Inc Lymphoma, B-Cell; Lymphoma, Non-Hodgkin Details
CD79b CAR-T cell therapy (Yake Biotechnology) Phase 1 Clinical Zhejiang University Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Biphenotypic, Acute Details
Iladatuzumab vedotin DCDS-0780A; RO-7032005 Phase 1 Clinical F. Hoffmann-La Roche Ltd Lymphoma, Non-Hodgkin Details

This web search service is supported by Google Inc.

totop

Laisser un message